Literature DB >> 27665954

An evaluation of the posterior cruciate ligament function in total knee arthroplasty with regard to its morphology and clinical properties.

D Marczak, J Kowalczewski, T Okoń, M Synder, M Sibiński1.   

Abstract

The aim of the study was to determine the degree of posterior cruciate ligament (PCL) degeneration and the reduction in the number of its mechanoreceptors, in patients with advanced degenerative joint disease. PCLs taken from study group of 50 patients in the mean age of 70.7 (53-84) years with a diagnosis of advanced idiopathic osteoarthritis undergoing condylar total knee arthroplasty were compared to those taken form the control group of 10 knee joints of cadavers. Groups were matched with regard to sex and age. Histological examination of PCLs of the study group showed changes of an inflammatory process and no significant signs of osteoarthritis in the control group. A close correlation was found between the severity of degenerative changes on the X-ray images according to the Ahlbäck scale, and the increased mucoid degeneration (p < 0.0001), the severity of the degeneration of the collagen structure (p < 0.0001) and the presence of proprioceptors of PCLs (p < 0.0001). Conserving the PCL by the use of type cruciate retaining knee arthroplasty does not guarantee the preservation of correct proprioceptive sensation.

Entities:  

Keywords:  function; knee replacement; osteoarthritis; posterior cruciate ligament; proprioception

Mesh:

Year:  2016        PMID: 27665954     DOI: 10.5603/FM.a2016.0047

Source DB:  PubMed          Journal:  Folia Morphol (Warsz)        ISSN: 0015-5659            Impact factor:   1.183


  1 in total

1.  QUANTIFICATION OF NEURAL ELEMENTS IN POSTERIOR CRUCIATE LIGAMENT: COMPARISON BETWEEN HEALTHY KNEES AND WITH PRIMARY OSTEOARTHROSIS.

Authors:  Marcelo Parente Oliveira; Roberto José Vieira DE Mello; Luciano Tavares Montenegro; Silvania Tavares Paz; Diego Ariel DE Lima; José Alberto Dias Leite
Journal:  Acta Ortop Bras       Date:  2021 Sep-Oct       Impact factor: 0.513

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.